Publications

Browse Publications:

By Category:

• Research Papers (111)
• Abstract Posters (2)
• Presentations (6)

By Physician:

• David Charytan, MD (3)
• Alanna Coolong, MD (2)
• Donald E. Cutlip, MD (52)
• Ralph D'Agostino, PhD (2)
• Elazer R. Edelman, MD, PhD (0)
• Maurizio Fava, MD (0)
• Lawrence Garcia, MD (0)
• Ernest V. Gervino, Sc.D., FACSM (1)
• Michael Gibson, MD (2)
• Kalon K.L. Ho, MD, MSc (21)
• Michael Jaff, MD (0)
• Mark Josephson, MD (4)
• Joseph Massaro, PhD (5)
• Laura Mauri, MD (23)
• Andrew Nierenberg, MD (0)
• Mark H. Pollack, MD (1)
• Jeffrey J. Popma, MD (40)
• Matthew R. Reynolds, M.D, M.Sc. (9)
• Alexei Shvilkin, MD, PhD (0)
• Peter Zimetbaum, MD (20)

Publications From: Donald E. Cutlip, MD

Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). Am J Cardiol. 2001 Mar 15;87(6):699-705.

Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004 Sep 7;110(10):1226-30.

Effects of stent length and lesion length on coronary restenosis. Am J Cardiol. 2004 Jun 1;93(11):1340-6, A5.

Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial. Am Heart J. 2001 Oct;142(4):648-56.

Coronary artery stenting in the aged. J Am Coll Cardiol. 2001 Mar 1;37(3):856-62.

Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001 Jan 15;87(2):152-6.

Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002 Nov 15;90(10):1079-83.

Impact of smoking on health-related quality of life after percutaneous coronary revascularization. Circulation. 2000 Sep 19;102(12):1369-74.

Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001 Jan 15;87(2):157-62.

Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008 Feb 12;117(6):790-7.

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 Mar 8;356(10):989-97.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 Mar 8;356(10):998-1008.

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9.

Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004 Oct 7;351(15):1493-501.

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 Dec 3;339(23):1665-71.

Defining the Risk of Late Stent Thrombosis

Bench to Bedside: Thrombosis

Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol. 2007 Sep 1;100(5):818-23.

Long-Term Results of Carotid Stenting versus Endarterectomy in High-Risk Patients. N Engl J Med 2008;358:1572-9.

Drug-Eluting Stenting for Unprotected Left Main Coronary Artery Disease. JACC February 21, 2006:878-81.

Cardiac Enzyme Elevation After Successful Percutaneous Coronary Intervention Is Not an Independent Predictor of Adverse Outcomes. Circulation 2005;112;916-923.

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13.

Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med. 2008 Apr 10;358(15):1572-9.

Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007 Jun 5;115(22):2842-7.

Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. Nephrol Dial Transplant. 2007 Sep;22(9):2578-85.

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.

Drug eluting stents for ST-elevation myocardial infarction: risk and benefit J Thromb Thrombolysis. 2007 Dec;24(3):293-9.

Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting. J Nephrol. 2006 Nov-Dec;19(6):764-70.

Drug-eluting stent era: will we improve 5-year outcomes? Coron Artery Dis. 2006 Dec;17(8):681-4.

Effect of Sirolimus-Eluting Stents versus Bare-Metal Stents on Outcomes Related to Restenosis and Disease Progression in Remote Coronary Segments

Impact of Target Lesion Revascularization During the First year After Bare-Metal or Sirolimus-Eluting Stenting on Five-Year Cardiac Outcomes

Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol. 2006 Sep 15;98(6):718-21.

Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006 Jul 4;48(1):32-6.

The Adoption of the 2000 European Society of Cardiology and American College of Cardiology Guidelines on Acute Coronary Syndrome Eliminated the Gender Difference in First-Year Survival

Drug-eluting stent era: will we improve 5-year outcomes? Coron Artery Dis. 2006 Dec;17(8):681-4.

The SIRIUS STudy: 5-Year Outcomes

Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006 Apr 4;47(7):1350-5.

Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation. 2005 Nov 1;112(18):2833-9.

Obesity and clinical restenosis after coronary stent placement. Am Heart J. 2005 Oct;150(4):821-6.

Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005 May 15;95(10):1140-5.

Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol. 2007 Oct 22;100(8B):56M-61M.

The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: Rationale and methods. J Vasc Surg. 2008 Apr 24.

Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304.

Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2007 Nov 27;50(22):2111-6.

Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts.Circulation. 2002 Mar 19;105(11):1285-90.

Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?Circulation. 2001 Aug 14;104(7):773-8.

Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001 Apr 17;103(15):1967-71.

Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002 Dec 18;40(12):2082-9.

Drug-eluting Stent Task Force: Final report and recommendations of the Working Committees on Cost-Effectiveness/Economics, Access to Care, and Mediolegal Issues. Catheter Cardiovasc Interv. 2004 May;62(1):1-17.

Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004 Feb 10;109(5):634-40.

Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). Am Heart J. 2003 May;145(5):84

Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv. 2003 Nov;60(3):344-51.

Meet The HCRI Team

Laura Fitzgerald

Manager Clinical Safety

Laura Fitzgerald joined HCRI in 2005 as the Manager of the Clinical Safety Department. Previously, she worked in the Clinical Safety and…

Submit an RFP

Quick Links

• Contact HCRI
• Careers at HCRI
• Information for Patients

930-W Commonwealth Avenue
Boston MA 02215
t: 617.632.1515    f: 617.632.1580

©2008 Harvard Clinical Research Institute